Pathogenic and non-pathogenic polyglutamine tracts have similar structural properties: towards a length-dependent toxicity gradient.

Abnormally expanded polyglutamine (polyQ) tracts provide a gain of toxic functions to nine otherwise unrelated human proteins and induce progressive neurodegenerative diseases. Over the past ten years, it was suggested that only polyQ tracts longer than a specific threshold adopt a particular structure, which would be the cause of the apparent polyQ length-dependent toxicity threshold observed in polyQ diseases. We have used a combination of biochemical and biophysical approaches to compare the structural properties of polyQ of pathogenic and non-pathogenic lengths under various conditions. We observe that pathogenic and non-pathogenic polyQ, as soluble species and upon interaction with a partner, during aggregation, or as mature aggregates, display very similar structural properties. PolyQ length only influences the aggregation kinetics and, to a lesser extent, the stability of the aggregates. We thus propose that polyQ toxicity does not depend on a structural transition occurring above a specific threshold, but rather that polyQ tracts are inherently toxic sequences, whose deleterious effect gradually increases with their length. We discuss how polyQ properties and other cellular factors may explain the existence of an apparent polyQ length-dependent toxicity threshold.

[1]  G P Bates,et al.  Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Dobson,et al.  Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution , 2003, Journal of Molecular Medicine.

[3]  S. Folstein,et al.  Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. , 1995, American journal of human genetics.

[4]  Michel Morange,et al.  Targeting expression of expanded polyglutamine proteins to the endoplasmic reticulum or mitochondria prevents their aggregation , 2004 .

[5]  E. Storey,et al.  Role of proteolysis in polyglutamine disorders , 2003, Journal of neuroscience research.

[6]  R. Karlsson,et al.  Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. , 1997, Journal of immunological methods.

[7]  M. Perutz,et al.  Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. , 1996, Current opinion in structural biology.

[8]  K. Lindsten,et al.  Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. , 2002, Human molecular genetics.

[9]  D. Dash,et al.  Role of histidine interruption in mitigating the pathological effects of long polyglutamine stretches in SCA1: A molecular approach , 2003, Protein science : a publication of the Protein Society.

[10]  S. A. Ross,et al.  A linear lattice model for polyglutamine in CAG-expansion diseases , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Wetzel,et al.  Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. , 2001, Journal of molecular biology.

[12]  Hans Lehrach,et al.  Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo , 1997, Cell.

[13]  M. Hayden,et al.  Familial influence on age of onset among siblings with Huntington disease. , 2001, American journal of medical genetics.

[14]  Christine Van Broeckhoven,et al.  Pathogenesis of polyglutamine disorders: aggregation revisited. , 2003, Human molecular genetics.

[15]  E. Hirsch,et al.  Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form , 1995, Nature Genetics.

[16]  H. Paulson,et al.  Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. , 2003, Current opinion in genetics & development.

[17]  Y. Agid,et al.  Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias , 1995, Nature.

[18]  P. Muchowski,et al.  Modulation of neurodegeneration by molecular chaperones , 2005, Nature Reviews Neuroscience.

[19]  Richard I. Morimoto,et al.  The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Ross,et al.  Protein aggregation and neurodegenerative disease , 2004, Nature Medicine.

[21]  Annalisa Pastore,et al.  From Alzheimer to Huntington: why is a structural understanding so difficult? , 2003, The EMBO journal.

[22]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[23]  Karen Marder,et al.  Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. MacDonald,et al.  HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. , 2005, Human molecular genetics.

[25]  J T Finch,et al.  Amyloid fibers are water-filled nanotubes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[27]  K. Davies,et al.  Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 'aggresomes' during oxidative stress, aging, and disease. , 2004, The international journal of biochemistry & cell biology.

[28]  C. Ross,et al.  What is the role of protein aggregation in neurodegeneration? , 2005, Nature Reviews Molecular Cell Biology.

[29]  G. Sobue,et al.  17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration , 2005, Nature Medicine.

[30]  T. Hashikawa,et al.  Intra- and Intermolecular β-Pleated Sheet Formation in Glutamine-repeat Inserted Myoglobin as a Model for Polyglutamine Diseases* , 2001, The Journal of Biological Chemistry.

[31]  Christopher M. Dobson,et al.  Molecular recycling within amyloid fibrils , 2005, Nature.

[32]  H. Zoghbi,et al.  Glutamine repeats and neurodegeneration. , 2000, Annual review of neuroscience.

[33]  P. Kebarle.  A brief overview of the present status of the mechanisms involved in electrospray mass spectrometry. , 2000, Journal of mass spectrometry : JMS.

[34]  Ronald Wetzel,et al.  Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  K. Fischbeck,et al.  Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy , 1991, Nature.

[36]  Annalisa Pastore,et al.  Solution structure of polyglutamine tracts in GST‐polyglutamine fusion proteins , 2002, FEBS letters.

[37]  Y. Trottier.  Antibody-based detection of CAG repeat expansion containing genes. , 2003, Methods in molecular biology.

[38]  V. Saudek,et al.  Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions , 1992, Journal of biomolecular NMR.

[39]  R. Wetzel,et al.  Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. , 2002, Human molecular genetics.

[40]  B. Friguet,et al.  Protein Degradation by the Proteasome and Its Implications in Aging , 2000, Annals of the New York Academy of Sciences.

[41]  J T Finch,et al.  Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.